Abstract
In this report, we describe the spontaneous malignant transformation of long-term cultured human fetal striatum neural stem cells (hsNSCs, passage 17). After subcutaneous transplantation of long-term cultured hsNSCs into immunodeficient nude mice, 2 out of 15 mice formed xenografts which expressed neuroendocrine tumor markers CgA and NSE. T1 cells, a cell line that we derived from one of the two subcutaneous xenografts, have undergone continuous expansion in vitro. These T1 cells showed stem cell-like features and expressed neural stem cell markers nestin and CD133. The T1 cells were involved in abnormal karyotype, genomic instability and fast proliferation. Importantly, after long-term in vitro culture, the T1 cells did not result in subcutaneous xenografts, but induced intracranial tumor formation, indicating that they adjusted themselves to the intracranial microenvironment. We further found that the T1 cells exhibited an overexpressed level of EGFR, and the CD133 positive T1 cells showed a truncation mutation in the exons 2-7 of the EGFR (EGFRvIII) gene. These results suggest that continuous expansion of neural stem cells in culture may lead to malignant spontaneous transformation. This phenomenon may be functionally related to EGFR by EGFRvIII gene mutation.
Keywords: tumorigenesis, malignant transformation, epidermal growth factor receptor (EGFR), xenograft
Introduction
Neural stem cells (NSCs) have the capability of self-renewal because at least one of the daughter cells maintains neural stem cell potential by asymmetric cell division. NSCs differentiate into three major neural cell types, neurons, oligodendrocytes and astrocytes 1. However, the proliferation and self-renewal properties of NSCs may cause malignant transformation 2. Although spontaneous malignant transformation was rarely observed, it has been suggested that the spontaneous transformation of adult stem cells, such as human mesenchymal stem cells (BM-hMSCs) and NSCs, can induce tumor formation 3-4. The spontaneous transformation of murine neural precursor cells has been reported by Johnson 5 and Florian 6. NSCs have been considered a promising tool for cell transplantation therapy and tissue engineering 7. In order to obtain a sufficient amount of NSCs for clinical use, extensive in vitro expansion of NSCs is usually necessary. However, it remains a concern regarding the security of the NSCs. A recent report revealed that the fetal neural stem cells transplanted into a patient with a hereditary neurodegenerative disease have grown into noncancerous tumors in the brain and spinal cord 8. Cancer stem cells have recently been identified as cancer-initiating cells for solid malignancies such as breast cancer 10 and pediatric brain tumors 11. Thus, normal NSCs may be prone to genomic instability and malignant transformation, particularly during long-term culture in vitro. Due to genomic instability, accumulation of DNA damage, loss of regulation in cell cycle, and deregulation of epigenetic signature may occur.
To investigate whether normal NSCs have tumorigenic potential, we inoculated human fetal striatum neural stem cells (hsNSCs) 12 subcutaneously into immunodeficient nude mice. We observed a spontaneous transformation of hsNSCs after 17 passages in vitro. Furthermore, a T1 tumor cell line that was derived from the hsNSCs following subcutaneous xenograft tumor formation was established and characterized. We found that the tumorigenicity of long-term cultured T1 cells showed strong selectivity in the microenvironment, which associated with the amplification of epidermal growth factor receptor (EGFR) gene and a constitutively active mutant form of the receptor, EGFRvIII.
MATERIALS AND METHODS
Culture and enrichment of human fetal striatum neural stem cells
The human fetal striatum neural stem cells were isolated and characterized as previously described 12.
In vivo tumorigenicity assays
All animal experiments were performed in accordance with the guidelines of the Animal Care Committee, Peking University Health Science Center. Immunodeficient nude mice (4-5 weeks of age) were purchased from the Experimental Animal Department, Peking University Health Science Center. Experimental group with 15 mice was injected with hsNSCs at passage 17 and was examined for tumorigenicity. Other 5 and 10 mice were used as positive control (injected with Hela cells) and negative control (injected with saline solution), respectively. 3×106 cells in 300 µl saline solution were subcutaneously injected into each mouse. The animals were monitored regularly for tumor occurrence throughout the whole experiment period.
Isolation and culture of primary tumor cells from subcutaneous xenografts
Immunodeficient nude mice with primary tumor formation were euthanized. The tumor cells were isolated, purified, and cultured in the primary culture medium of DMEM/F12 (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, USA), EGF (20 ng/ml, PeproTech, USA), bFGF (20 ng/ml, PeproTech, USA), and B27 (50x, Invitrogen, USA). When adherent clones reached about 95% confluence, they were transferred to a new flask and cultured continuously to form a monolayer. The populations of tumor cells were isolated from neoplasias after at least five passages. We named this cell population as T1 cells.
Serial subcutaneous xenografts
The xenograft tissues were obtained through serial subcutaneous passage in immunodeficient nude mice. Small non-necrotic xenograft tissues were mechanically crumbled and passed through a 100-µm cell sieve (Falcon). Then 4-week-old immunodeficient nude mice were implanted subcutaneously with tiny tissue fragments of the xenografts. The animals were monitored regularly for tumor occurrence throughout the whole survival period. Five mice were inoculated for each experiment. The tumor formation rate and the size of the neoplasias were recorded, and the experiment was repeated.
G-banding Chromosome Analysis
Cell chromosome analysis was performed using the conventional Giemsa staining. Karyotypic analysis was performed using an Olympus microscope (Optronic cooled CCD) and the dedicated cytoscan-karyotyping FISH & CGH system (United Biotechnology USA corporation).
DNA fingerprinting analysis using human short tandem repeat (STR) markers
DNA fingerprinting analysis was performed using genomic DNA from NSCs (passage 9 and 17). The control cells and T1 cells were examined for human STR marker expression using the PowerPlex® 16 System Kit (Promega Corp, Madison, WI) on an automated ABI 310 Genetic Analyzer (Applied Biosystems, Foster City, CA).
Measurement of cell proliferation
For cell cycle analysis, DNA was labeled with 20 μg/ml propidium iodine (Sigma, USA). The cell cycle was analyzed using FACScalibur flow cytometry with ModiFit software. For the PCNA analysis, nuclear antigen was stained with fluorescein (Fluorescein isothiocyanate, FITC) labeled with anti-PCNA antibody (Becton Dicksinson). Mouse FITC-IgG2a (Becton Dicksinson) was used as isotype control. Stained cells were analyzed using FACScalibur flow cytometry (Becton Dicksinson). The result was shown as the overlaid histograms of PCNA with its isotype control.
Flow Cytometric Immunophenotypic Studies
For membrane antigen staining, cells were trypsinized into single cell suspension in a total volume of 100µl PBS/BSA and immediately stained for 15min at room temperature in darkness with fluorescein (FITC) labeled antibodies, including anti-CD133, CD117, CXCR4 and EGFR. Mouse IgG2a-FITC or IgG1-FITC (Becton-Dickinson) was used as isotype control. Stained cells were analyzed by FACScalibur flow cytometry (Becton-Dickinson).
Intracranial tumorigenic assays
Ten immunodeficient nude mice were divided equally into the experimental group and control group. 5×105 isolated tumor cells were intracranially injected into five immunodeficient nude mice. When symptom of hydrocephalus was observed, the intact brains were removed and paraffin embedded for H&E staining. Normal human fetal striatum neural stem cells were injected into the control mice. All surgical interventions and animal care were provided in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
Immunofluorescence assays
To stain the cytoplasmic and nuclear proteins, cells were incubated with relevant primary antibodies at 4℃ overnight and subsequently with appropriate secondary fluorescence-conjugated antibodies. Mouse or rabbit normal serum was used as a negative control. The primary antibodies included a mouse anti-human antibody specific for nuclei (Chemicon, 1:100), a mouse anti-human antibody specific for the epidermal growth factor receptor (Chemicon, 1:100), and a rabbit anti-GFAP polyclonal antibody (Chemicon, 1:100). DAPI was used for nuclear staining. Fluorescence signals were detected using a Confocal microscope (Leica TCS SP5, German) or an Olympus immuno-fluorescent microscope (Model BX51TR) with an Apogee Instruments Microscopy Fluorescence System (Model KX85).
Purification of CD133+ cells
CD133+ cells were purified by magnetic cell sorting (MACS) using the CD133 MicroBead Kit (Miltenyi Biotech), and analyzed by the flow cytometry system using CD133/2-PE (Miltenyi Biotech). For reverse-transcriptase-PCR (RT-PCR) assay, total RNA was extracted from the sorted CD133+ cells. Complementary DNA (cDNA) was synthesized. 5' (sense) primer was: 5'-CTTCGGGGAGCAGCGATGCG AC-3', 3' (antisense) primer was: 5'- ACCAATACCTATTCCGTTACAC-3'. RT-PCR products yielded two fragments, a 1044-bp (wild-type) fragment and a 243-bp (deletion product) fragment. PCR products were subcloned into the pGEM-T easy cloning vector (Invitrogen) and sequenced.
RESULTS
Transformation of Long-term Cultured hsNSCs as Revealed in Subcutaneous Xenograft
Among the 15 mice transplanted with cultured hsNSCs (passage 17), xenografts formed in two mice 3 months after implantation (Fig. 1A, 1B), whereas tumors formed in five of five mice transplanted with Hela cells. No tumor was formed in the negative control mice injected with saline (data not shown). These results suggested a risk of tumorigenesis from the transplantation of long-term cultured hsNSCs. The H&E staining results showed that the neoplasias proliferated actively and were of heterogeneity of nucleus (Fig. 1E,1F). The immunohistochemistry results indicated that, pathologically, these tumors belonged to the neuroblastoma-like tissue pattern (Fig. 1G-1L). They were positive for CgA (Fig. 1G) and NSE (Fig. 1H), but were negative for CD99 (Fig. 1I), cytokeratin AE1/AE3 (Fig. 1J), synaptophysin (Fig. 1K) and GFAP (Fig. 1L). The tumor cells form the hsNSC injected mice was isolated, purified and cultured, we named them as T1 cells. The Karyotype analyses were performed on passage 17 hsNSCs and the T1 cells. Metaphases were determined for each karyotype analysis, and the representative karyotype was shown in Fig 1C and 1D. The chromosome dispersion of the T1 cells ranged from 60 to 70 chromosomes. A large number of different numerical and structural chromosomal aberrations were detected in the T1 cells but not in the parent hsNSCs, which showed a normal complement of chromosomes and no genetic abnormality (Fig. 1C, 1D).
Establishment and characterization of the T1 cell line
T1 cells were isolated as described in the Materials and Methods. To evaluate the proliferation capacity of the T1 cells, the cell cycle was analyzed by flow cytometry. The percentages were 42.60% for the S phase cells (Fig. 2A), and 91.46% positive for the proliferation cell nuclear antigen (PCNA) (Fig. 2B). By the end of a period of at least five passages, the two types of cells exhibited the homogeneous morphology. At passage 5, the T1 cell line was purified, and mouse cell contamination was not detected using an anti-human nucleus antibody (Fig. 2C). A short tandem repeat (STR) analysis, which was conducted by the Center of Forensic Sciences Beijing Genomics Institute, was employed to monitor the genomic instability. STR loci consisted of short, repetitive sequence elements with 3 to 7 base pairs in length. The STR markers were employed to detect the variability between the T1 cells and the hsNSCs. The boxed numbers and corresponding peaks between the hsNSCs and the T1 cells were different (Fig. 2D-2F). These alterations indicated that the T1 cell line exhibited genomic instability. Based on these data, the T1 cells were confirmed as a pure population of tumor cells that originated from the transformation of the hsNSCs.
Immunophenotype analysis of parental neural stem cells (hsNSCs) and T1 cells by FACS
Variable levels of antigen expression were observed for the markers of cell's capacity of division and proliferation in the study, as shown in Fig 3. PCNA analysis results showed that T1 cells had a proliferative capacity that was stronger than the hsNSCs (Fig. 3A, B). Upon staining hsNSCs and T1 cells simultaneously for CD117, CXCR4, we observed a marked upregulated expression in T1 cells (Fig. 3C-F). In contrast, the expression of CD133 in hsNSCs and T1 cells was relatively uniform (Fig. 3G, 3H). Together, these data had revealed certain important molecular and biological changes that could contribute to the tumorigenicity of T1 cell line.
The neoplasias of long-term cultured T1 cells were restricted in the brain after transplantation into nude mice
To determine the in vivo tumorigenicity, the xenograft tissues were obtained through serial subcutaneous passage in immunodeficient nude mice according to the method described in the Material and Methods section. Serial subcutaneous transplantations of T1 xenograft tissues were performed and measured in the immunodeficient nude mice (Fig. 4A). However, we were surprised that during long-term in vitro culture, the T1 cells did not result in xenografts subcutaneously. Since the T1 cells were transformed from neural stem cells, we injected the T1 cells that were cultured in vitro for long periods of time into the brains of immunodeficient nude mice to test intracranial neoplasias. After one to two months, all five nude mice were fleshless and unresponsive. Histologically, the intracranial neoplasias were poorly differentiated tumors (Fig. 4B, 4C). These tumor cells invaded the surrounding normal nervous tissues. H&E staining analysis revealed that these tumor cells had large, oval nuclei with some prominent nucleoli. Spindles or equatorial planes were also observed in some tumor cells, implying that these tumor cells could proliferate quickly (Fig. 4B, 4C). Immunofluorescence analysis indicated that the GFAP of the intracranial neoplasias was changed from the negative to positive in the subcutaneous xenografts (Fig. 4D-4F). H&E staining (Fig 4G, 4H) show the sections of nude mice brain with hsNSC transplantation. Black arrow indicates the neural scar after neural stem cells transplantation. White arrow indicates the needle trajectory of neural stem cells transplantation (Scale bar: 1000μm). These data indicated that the T1 cells could grow into tumors in the brain, and the neoplasias were similar to tumors derived from the nervous system.
T1 cell line shows stem cell-like features and initiates intracranial tumor formation
From the results demonstrated above, the T1 cells exhibited strong proliferation activities. We further found that these T1 cells showed stem cell-like features and expressed neural stem cell markers nestin and CD133 (Fig. 5A). The environmental factors involved in the T1 cell line were also determined. Both CXCR4 (Fig. 5B) and EGFR (Fig. 5C) were detected during brain tumorigenesis. EGFRvIII was also identified in the T1 cells (Fig. 5D). CXCR4 in the T1 cells showed polarity (Fig. 5B), indicating that the T1 cells possessed the potential for migration under the action of chemokines. The sections of tumor tissues derived from T1 cell intracranial transplantation also expressed CXCR4, EGFR and EGFRvIII (Fig. 5E-5G). The glial cell marker GFAP was still positive (Fig. 5G). It is known that the mutant of the EGFR gene EGFRvIII was involved in the majority of cases of glioblastoma multiforme (GBMs) with EGFR amplification 13. Thus, we separated CD133(+) and CD133(-) cells from the intracranial T1 tumors using the CD133-specific antibody (Fig.5I), and then determined the status of the EGFRvIII mutant. The RT-PCR assay was used to analyze the EGFRvIII mutation. We found that the CD133(-) T1 cells showed both the EGFR (1044-bp) and EGFRvIII (243-bp) bands, while the CD133(+) T1 cells only showed the EGFRvIII band (Fig. 5H). The sequencing result of the EGFRvIII gene was shown in Fig.5J. Together, these data suggest that EGFRvIII played an important role in the brain tumor formation.
DISCUSSION
Adult human neural stem cells have been considered as a resource for cell therapy and tissue engineering 7, 13-14. Due to their capabilities of self-renewal and differentiation towards the neural cells, NSCs provide an attractive tool for transplantation-based therapy of neurodegenerative diseases 15-16. In vitro NSC expansion makes it possible to obtain sufficient amounts of NSCs for clinical use. However, a potential risk of NSC treatment might arise in that NSCs can paradoxically promote tumorigenesis. It has been reported that after prolonged in vitro culture, human adipose derived MSCs, murine bone marrow derived stem cells, and NSCs can become tumorigenic 3-6. Long-term in vitro cultured NSCs may be particularly prone to genomic instability. Therefore, it is critical to evaluate the risk of human NSCs transformation after long-term in vitro culture.
In this study, following long-term hsNSC culture in vitro, we observed spontaneous malignant transformation following the subcutaneous transplantation of hsNSCs into immunodeficient nude mice. We established a T1 cell line derived from the tumor growing out of the transformed hsNSCs at passage 17 following subcutaneous xenograft. The T1 cell line showed stem cell-like features and expressed neural stem cell markers nestin and CD133. STR analysis indicated critical genomic instability that might have led to the transformation of hsNSCs. Thus, the T1 cells were involved in the abnormal karyotypes and genomic instability. Genetic alteration such as amplifications, mutations or deletions of genes might lead to a decoupling of the biological mechanisms involved in the regulation of normal cell growth and differentiation 11,17-20. A difference between serial subcutaneous and intracranial tumorigenesis was observed in this study. During long-term in vitro culture, the T1 cells did not result in subcutaneous xenograft, but led to obvious intracranial tumor formation, indicating that these cells adjusted themselves to the intracranial microenvironment. The neoplasias were restricted in the brain and they opted for selecting their favorite microenvironment. Although it remains largely unknown why the transformations of the hsNSCs and T1 cells occurred in response to distinct microenvironments, it has been widely accepted that the host microenvironment plays a crucial role in cancer initiation and progression 21-23.
We detected strongly CD117 (KIT) expression in T1 cells using FACS. A growing body of evidence suggests that the KIT receptor involved in SCF signaling is highly activated, which enhances endothelial cell proliferation in the brain microvasculature both in vivo and in vitro 24-25. Both CXCR4 and EGFR are critical receptors involved in biological pathways because of their roles in inflammation, development and tumorigenesis 26-28. CXCR4 is an important molecule involved in the spread and progression of a variety of tumors 26,29-31. Recent investigations have revealed that chemokines are often up-regulated within areas of brain pathology and may provide crucial signaling cues for stem cell migration 23,32. Overexpression or activation of the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase associated with cell proliferation and survival, is often found in tumors33. Crosstalk between EGFR and CXCR4 has recently been found to play an important role in the development of tumors 34. Our findings revealed that T1 cells overexpress EGFR, and the CD133 positive T1 cells show a truncation mutation in the exons 2-7 of the EGFR gene (EGFRvIII). EGFRvIII is caused by deletion of exons 2 to 7, resulting in a protein that lacks a ligand-binding domain and is constitutively activated. EGFRvIII is further resistant to down-regulation due to a low rate of receptor endocytosis 35-37. Mutant forms of the EGFR gene have been reported to participate in tumorigenesis for patients with malignant gliomas 38-40.
In conclusion, our results strongly suggest that the risk of malignant spontaneous transformation might result from the genomic instability caused by the continuous expansion of neural stem cells in vitro. The microenvironments play a crucial role in the intracranial tumor initiation and progression. Since the mutant EGFR gene EGFRvIII was involved in the majority of cases of glioblastoma multiforme with EGFR amplification 13, the intracranial tumor formation observed in our study might be related to the EGFRvIII gene during the process of tumorigenesis.
Acknowledgments
This work was supported by the National Natural Science Foundation of China (grant 30471638) and the Beijing Natural Science Foundation (grant 7062041). This work was also supported by the Foundation of National Science and Technology Major Project Focusing on Drug Innovation from The Ministry of Science and Technology of the People's Republic of China and The National Basic Research Program of China 973 Project (grant 2011CB510200 and 2011CB707700). This work was partially supported by the Gillson Longenbaugh Foundation.
References
- 1.Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell. 1990;60:585–595. doi: 10.1016/0092-8674(90)90662-x. [DOI] [PubMed] [Google Scholar]
- 2.Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006;6:425–436. doi: 10.1038/nrc1889. [DOI] [PubMed] [Google Scholar]
- 3.Røsland GV, Svendsen A, Torsvik A. et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009;69:5331–5339. doi: 10.1158/0008-5472.CAN-08-4630. [DOI] [PubMed] [Google Scholar]
- 4.Casalbore P, Budoni M, Ricci-Vitiani L. et al. Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1. PLoS One. 2009;4:e4434. doi: 10.1371/journal.pone.0004434. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Radtke C, Redeker J, Jokuszies A. et al. In vivo transformation of neural stem cells following transplantation in the injured nervous system. J Reconstr Microsurg. 2010;26:211–212. doi: 10.1055/s-0029-1238221. [DOI] [PubMed] [Google Scholar]
- 6.Siebzehnrubl FA, Jeske I, Müller D. et al. Spontaneous in vitro transformation of adult neural precursors into stem-like cancer cells. Brain Pathol. 2009;19:399–408. doi: 10.1111/j.1750-3639.2008.00189.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Tang XQ, Heron P, Mashburn C. et al. Targeting sensory axon regeneration in adult spinal cord. J Neurosci. 2007;27:6068–6078. doi: 10.1523/JNEUROSCI.1442-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Amariglio N, Hirshberg A, Scheithauer BW. et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6:e1000029. doi: 10.1371/journal.pmed.1000029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Al-Hajj M, Wicha MS, Benito-Hernandez A. et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. doi: 10.1073/pnas.0530291100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hemmati HD, Nakano I, Lazareff JA. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100:15178–15183. doi: 10.1073/pnas.2036535100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Furnari FB, Fenton T, Bachoo RM. et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–2710. doi: 10.1101/gad.1596707. [DOI] [PubMed] [Google Scholar]
- 12.Li X, Xu J, Bai Y. et al. Isolation and characterization of neural stem cells from human fetal striatum. Biochem Biophys Res Commun. 2005;326:425–434. doi: 10.1016/j.bbrc.2004.11.044. [DOI] [PubMed] [Google Scholar]
- 13.Mapara KY, Stevenson CB, Thompson RC. et al. Stem cells as vehicles for the treatment of brain cancer. Neurosurg Clin N Am. 2007;18:71–80. doi: 10.1016/j.nec.2006.10.001. [DOI] [PubMed] [Google Scholar]
- 14.Clarke DL, Johansson CB, Wilbertz J. et al. Generalized potential of adult neural stem cells. Science. 2000;288:1660–1663. doi: 10.1126/science.288.5471.1660. [DOI] [PubMed] [Google Scholar]
- 15.Bjorklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci. 2000;3:537–544. doi: 10.1038/75705. [DOI] [PubMed] [Google Scholar]
- 16.Horner PJ, Gage FH. Regenerating the damaged central nervous system. Nature. 2000;407:963–970. doi: 10.1038/35039559. [DOI] [PubMed] [Google Scholar]
- 17.Lagasse E. Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. Gene Ther. 2008;15:136–142. doi: 10.1038/sj.gt.3303068. [DOI] [PubMed] [Google Scholar]
- 18.Kelly S, Bliss TM, Shah AK. et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A. 2004;101:11839–11844. doi: 10.1073/pnas.0404474101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Micallef J, Taccone M, Mukherjee J. et al. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res. 2009;69:7548–7556. doi: 10.1158/0008-5472.CAN-08-4783. [DOI] [PubMed] [Google Scholar]
- 20.Maher EA, Furnari FB, Bachoo RM. et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15:1311–1333. doi: 10.1101/gad.891601. [DOI] [PubMed] [Google Scholar]
- 21.Calabrese C, Poppleton H, Kocak M. et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69–82. doi: 10.1016/j.ccr.2006.11.020. [DOI] [PubMed] [Google Scholar]
- 22.Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733–736. doi: 10.1038/nrc2246. [DOI] [PubMed] [Google Scholar]
- 23.Imitola J, Raddassi K, Park KI. et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A. 2004;101:18117–18122. doi: 10.1073/pnas.0408258102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Han Z, Ren H, Zhao H. et al. Hypoxia-inducible factor (HIF)-1{alpha} directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF) Carcinogenesis. 2008;29:1853–1861. doi: 10.1093/carcin/bgn066. [DOI] [PubMed] [Google Scholar]
- 25.Sun L, Hui A, Su Q. et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9:287–300. doi: 10.1016/j.ccr.2006.03.003. [DOI] [PubMed] [Google Scholar]
- 26.Tachibana K, Hirota S, Iizasa H. et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393:591–594. doi: 10.1038/31261. [DOI] [PubMed] [Google Scholar]
- 27.Liu Y, Ji R, Li J. et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res. 2010;29:16. doi: 10.1186/1756-9966-29-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–225. doi: 10.1016/s0092-8674(00)00114-8. [DOI] [PubMed] [Google Scholar]
- 29.Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–1767. doi: 10.1182/blood-2005-08-3182. [DOI] [PubMed] [Google Scholar]
- 30.Eck SM, Cote AL, Winkelman WD. et al. CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol Cancer Res. 2009;7:1033–1044. doi: 10.1158/1541-7786.MCR-09-0015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Porcile C, Bajetto A, Barbero S. et al. CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann N Y Acad Sci. 2004;1030:162–169. doi: 10.1196/annals.1329.021. [DOI] [PubMed] [Google Scholar]
- 32.Schonemeier B, Schulz S, Hoellt V. et al. Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. J Neuroimmunol. 2008;198:39–45. doi: 10.1016/j.jneuroim.2008.04.010. [DOI] [PubMed] [Google Scholar]
- 33.Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–15. doi: 10.1016/s0959-8049(01)00231-3. [DOI] [PubMed] [Google Scholar]
- 34.Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 2000;275:6868–6875. doi: 10.1074/jbc.275.10.6868. [DOI] [PubMed] [Google Scholar]
- 35.Grandal MV, Zandi R, Pedersen MW. et al. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis. 2007;28:1408–1417. doi: 10.1093/carcin/bgm058. [DOI] [PubMed] [Google Scholar]
- 36.Rossi G, Marchioni A, Longo L. EGFR mutations and sensitivity to gefitinib. N Engl J Med. 2004;351:1260–1261. [PubMed] [Google Scholar]
- 37.Lee JC, Vivanco I, Beroukhim R. et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006;3:e485. doi: 10.1371/journal.pmed.0030485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification--rearrangement in human glioblastomas. Int J Cancer. 1995;62:145–148. doi: 10.1002/ijc.2910620206. [DOI] [PubMed] [Google Scholar]
- 39.Bax DA, Gaspar N, Little SE. et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res. 2009;15:5753–5761. doi: 10.1158/1078-0432.CCR-08-3210. [DOI] [PubMed] [Google Scholar]
- 40.Inda MM, Bonavia R, Mukasa A. et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010;24:1731–1745. doi: 10.1101/gad.1890510. [DOI] [PMC free article] [PubMed] [Google Scholar]